A multicenter phase II study of regorafenib in patients (pts) with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib (IM) and sunitinib (SU).
S. George
Consultant or Advisory Role - Novartis
Research Funding - Bayer; Novartis; Pfizer
M. von Mehren
No relevant relationships to disclose
M. C. Heinrich
Consultant or Advisory Role - Novartis; Pfizer
Honoraria - Novartis
Research Funding - Novartis
Q. Wang
No relevant relationships to disclose
C. L. Corless
No relevant relationships to disclose
J. E. Butrynski
No relevant relationships to disclose
J. A. Morgan
No relevant relationships to disclose
A. J. Wagner
Consultant or Advisory Role - Novartis; Pfizer
Honoraria - Novartis
Research Funding - Novartis
E. Choy
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Novartis; Pharmacyclics
W. D. Tap
No relevant relationships to disclose
J. Manola
No relevant relationships to disclose
J. T. Yap
Research Funding - Bayer
A. D. Van Den Abbeele
Research Funding - Bayer
S. Solomon
No relevant relationships to disclose
J. A. Fletcher
No relevant relationships to disclose
G. D. Demetri
Consultant or Advisory Role - Alnylam; Amgen; ARIAD; ArQule; Bayer; Champions Biotechnology; Daiichi Sankyo; EMD Serono; Enzon; Genentech; GlaxoSmithKline; Idera Pharmaceuticals; Infinity; Johnson & Johnson; Kolltan Pharmaceuticals; Millennium; N-of-One (U); Novartis; Pfizer; Plexxikon; ZIOPHARM Oncology
Stock Ownership - Champions Biotechnology; Kolltan Pharmaceuticals; N-of-One ; Plexxikon
Honoraria - Novartis; Pfizer
Research Funding - ARIAD; Bristol-Myers Squibb; Daiichi Sankyo; Infinity; Johnson & Johnson; Novartis; Pfizer
Expert Testimony - ARIAD (U); Bayer (U); Infinity (U); Johnson & Johnson (U); Novartis (U); Pfizer (U)